Similarly, a phase II trial (A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti-PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma) is evaluating, in 176 patients with unresectable or metastatic BRAF-V600 mutant melanoma, the safety and efficacy of atezolizumab (arm A) or vemurafenib and cobimetinib (arm B) after a 3-month run-in period with vemurafenib plus cobimetinib [57]. Here, CD274 is linked to melanoma.